Price
$0.07+6.99%Social Signal Score
Revenue
$19.6K+538.30%Company Profile
- CEO
- Hugh MacNaught
- Sector
- Healthcare
- Industry
- Medical - Devices
- Employees
- 3
- Beta
- 0.04
- Country
- CA
- Piotroski score
- 5 / 9 (Middling)
- Altman Z-score
- -162.04
Financials
Revenue
$19.6K+538.3%Net Income
$-683.0KEBITDA
$0.00Free Cash Flow
$-614.4KEPS (diluted)
$-0.00Shares Outstanding (diluted)
186.75M+671.4%Operating Expenses
$527.6KCash & Debt
$333.6KQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $179.8K | $-3.20M | $-0.02 |
| 2024 | $95.2K | $-4.92M | $-0.03 |
| 2023 | $49.2K | $-4.87M | $-0.03 |
| 2022 | $68.2K | $-4.87M | $-0.03 |
| 2021 | $0.00 | $-3.88M | $-0.03 |
| 2020 | $36.0K | $-1.85M | $-0.02 |
| 2019 | $81.0K | $-3.32M | $-0.05 |
| 2018 | $60.2K | $-2.08M | $-0.04 |
| 2017 | $38.9K | $-3.70M | $-0.08 |
| 2016 | $209.5K | $-2.62M | $-0.10 |
| 2015 | $55.8K | $-1.51M | $-0.07 |
| 2014 | $128.3K | $-2.19M | $-0.13 |
| 2013 | $71.0K | $-1.65M | $-0.12 |
| 2012 | $372.3K | $-4.02M | $-0.32 |
Valuation
VPTDFhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
100+7.14%Social Signal Score
Mentions (3)
- Newsthenewswire.com·12d ago·Neutral
…Quality and Regulatory Audits Toronto, Ontario (September 24, 2026) – TheNewswire - Ventripoint Diagnostics Ltd. (" Ventripoint " or the " Company "), (TSXV:VPT; OTC:VPTDF) today announced the completion of its annual quality and regulatory audits covering the Medical Device Single Audit Program (MDSAP), ISO 13485:2016 Quality Management System and the European Union Medical Device Regulation (MDR 2017/745). The completion of the audits confirms the continued effectiveness of Ventripoint's quali…
View source ↗ - Newsglobenewswire.com·55d ago·Neutral
Ventripoint Expands Subscription Access for FDA-Cleared AI Cardiac Imaging TORONTO, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Company”) (TSXV: VPT; OTC: VPTDF), a leader in AI-assisted cardiac imaging, today announced the next phase of its commercial strategy for VMS+™ 4.0, its FDA-cleared platform that turns standard heart-ultrasound images into three-dimensional cardiac measurements.
View source ↗ - Newsthenewswire.com·59d ago·Neutral
Ventripoint Diagnostics Announces Cancellation and Re-Grant of Options, Grant of Annual Incentive Options and Private Placement Toronto, Ontario – The Newswire – August 7, 2026 - Ventripoint Diagnostics Ltd. (" Ventripoint " or the " Company ") (TSXV:VPT; OTC:VPTDF) announces that it incorrectly granted 7,246,250 stock options of the Company to various officers, employees and consultants of the Company during the period of February 27, 2025 to May 27, 2026 as the Company did not obtain the neces
View source ↗
Earnings
Thu, Nov 26(in 7 weeks)
Estimates and results for VPTDF via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Congress trades
No disclosed congressional trades in VPTDF.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.